Cardiovascular Disease Clinical Trial
Official title:
The Effects of Buttermilk With or Without Lutein-enriched Egg Yolk on the Serum LDL Cholesterol Concentration of Slightly Hypercholesterolaemic Volunteers
Verified date | September 2018 |
Source | Maastricht University Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Rationale and objective:
Based on the results of a pilot study, the objective of the present study is to evaluate
whether buttermilk lower serum LDL cholesterol concentrations and can prevent the serum LDL
cholesterol raising effects of eggs.
Study Design:
The study has a randomized placebo-controlled factorial 2x2 design. The total study duration
is 14 weeks, consisting of a 2 weeks run-in period and a 12 weeks experimental period.
Subjects will be stratified for age, gender and BMI over the experimental groups.
Study population:
One hundred and eight healthy male and female subjects, aged 18-70 years, with slightly
elevated serum total cholesterol concentrations (5.5-8.0 mmol/l).
Intervention:
During the entire study period, volunteers are instructed to consume a diet according to the
Dutch dietary guidelines (35 en% fat (10 en% saturated fat), 50-55 en% carbohydrates). During
the two weeks run-in period all subjects will drink daily at lunch 100 mL skimmed milk.
During the 12 weeks experimental period, a first group of subjects will continue drinking the
skimmed milk (control group), while a second group will consume a low-fat buttermilk, a third
group skimmed milk enriched with egg-yolk, and a fourth group egg-yolk incorporated into a
low-fat buttermilk based beverage. The egg-yolk will be enriched in lutein. Whole egg
consumption (others than provided by us) is not allowed during the entire study.
Main study parameters/endpoints:
Measurements will be performed during the run-in period (days 0, 11 and 14) and during the
experimental period (days 56, 95 and 98). The main effects (egg-yolk and buttermilk
consumption) will be calculated as the absolute differences between values obtained at the
end of the experimental (average days 95 and 98) and run-in (average days 11 and 14) periods.
The primary endpoint is the change in serum LDL cholesterol concentrations. Secondary
endpoints are changes in serum total and HDL cholesterol, triacylglycerol, apoA-I, apoB and
hsCRP concentrations.
Status | Completed |
Enrollment | 108 |
Est. completion date | December 1, 2012 |
Est. primary completion date | May 1, 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Aged between 18 and 70 years - Fasting serum total cholesterol between 5.5 - 8.0 mmol/l - Fasting plasma glucose < 7.0 mmol/l - BMI between 25-30 kg/m2 - non-smoking - Willingness to abstain for the duration of the study from egg consumption Exclusion Criteria: - unstable body weight (weight gain or loss >3 kg in the past 3 months) - allergic for eggs or egg-rich products - allergic or intolerant for cow-milk (lactose) based products - indication for treatment with cholesterol-lowering drugs according to the Dutch Cholesterol Consensus - use of medication or a diet known to affect serum lipid or glucose metabolism - active cardiovascular disease (for instance congestive heart failure) or recent (<6 months) event, such as acute myocardial infarction or cerebro-vascular accident - not willing to stop the consumption of vitamin supplements, fish oil capsules or products rich in plant stanol or sterol esters 3 weeks before the start of the study - men: consumption of >21 alcohol consumptions a week - women: consumption of >14 alcohol consumptions a week - abuse of drugs - pregnant or breastfeeding women - participation in another biomedical study within 1 month prior to the screening visit - having donated blood (as blood donor) within 1 month prior to the screening visit or planning to do so during the study - impossible or difficult venipuncture as evidenced during the screening visits |
Country | Name | City | State |
---|---|---|---|
Netherlands | Maastricht University | Maastricht | Limburg |
Lead Sponsor | Collaborator |
---|---|
Maastricht University Medical Center |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in serum LDL cholesterol concentrations | LDL cholesterol will be measured at day 0, 11, 14, 56, 95 and 98 during the study | ||
Secondary | Changes in serum total and HDL cholesterol, triacylglycerol, apoA-I, apoB and hsCRP concentrations | Serum total and HDL cholesterol, triacylglycerol, apoA-I and ApoB will be measured at day 0, 11, 14, 56, 95 and 98 during the study. hsCRP concentrations will be measured at day 11, 14, 95 and 98. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02122198 -
Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women
|
N/A | |
Completed |
NCT02502812 -
Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04216342 -
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03654313 -
Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
|
Phase 1 | |
Completed |
NCT03646656 -
Heart Health Buddies: Peer Support to Decrease CVD Risk
|
N/A | |
Completed |
NCT02081066 -
Identification of CETP as a Marker of Atherosclerosis
|
N/A | |
Completed |
NCT02147626 -
Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia
|
N/A | |
Not yet recruiting |
NCT06405880 -
Pharmacist Case Finding and Intervention for Vascular Prevention Trial
|
N/A | |
Recruiting |
NCT03095261 -
Incentives in Cardiac Rehabilitation
|
N/A | |
Completed |
NCT02868710 -
Individual Variability to Aerobic Exercise Training
|
N/A | |
Completed |
NCT02998918 -
Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL
|
N/A | |
Not yet recruiting |
NCT02578355 -
National Plaque Registry and Database
|
N/A | |
Completed |
NCT02589769 -
Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons
|
N/A | |
Completed |
NCT02711878 -
Healing Hearts and Mending Minds in Older Adults Living With HIV
|
N/A | |
Recruiting |
NCT02885792 -
Coronary Artery Disease in Patients Suffering From Schizophrenia
|
N/A | |
Completed |
NCT02640859 -
Investigation of Metabolic Risk in Korean Adults
|
||
Completed |
NCT02652975 -
Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium
|
N/A | |
Completed |
NCT02272946 -
Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk
|
Phase 2 | |
Completed |
NCT02657382 -
Mental Stress Ischemia: Biofeedback Study
|
N/A | |
Recruiting |
NCT02265250 -
Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment
|